Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Zalutumumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Zalutumumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Zalutumumab. |
| Estrone | Estrone may increase the thrombogenic activities of Zalutumumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Zalutumumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Zalutumumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Zalutumumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Zalutumumab. |
| Estriol | Estriol may increase the thrombogenic activities of Zalutumumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Zalutumumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Zalutumumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Zalutumumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Zalutumumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Zalutumumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Zalutumumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Zalutumumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Zalutumumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Zalutumumab. |
| Equol | Equol may increase the thrombogenic activities of Zalutumumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Zalutumumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Zalutumumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Zalutumumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Zalutumumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Zalutumumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Zalutumumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Zalutumumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Zalutumumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Zalutumumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Zalutumumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Zalutumumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Zalutumumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Zalutumumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Zalutumumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Zalutumumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Zalutumumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zalutumumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Zalutumumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Zalutumumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Zalutumumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Zalutumumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Zalutumumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Zalutumumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Zalutumumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zalutumumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Zalutumumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zalutumumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Zalutumumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Zalutumumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zalutumumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Zalutumumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Zalutumumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Zalutumumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zalutumumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Zalutumumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Zalutumumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Zalutumumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Zalutumumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Zalutumumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Zalutumumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Zalutumumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Zalutumumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Zalutumumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Zalutumumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Zalutumumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Zalutumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Zalutumumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Zalutumumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Zalutumumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Zalutumumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Zalutumumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Zalutumumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Zalutumumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Zalutumumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Zalutumumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Zalutumumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Zalutumumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Zalutumumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Zalutumumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Zalutumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Zalutumumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Zalutumumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Zalutumumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Zalutumumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Zalutumumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Zalutumumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Zalutumumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Zalutumumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Zalutumumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Zalutumumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Zalutumumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Zalutumumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Zalutumumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Zalutumumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Zalutumumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Zalutumumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Zalutumumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Zalutumumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Zalutumumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Zalutumumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Zalutumumab. |